Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that will make the kidney disease drug developer the first U.S. biotech ...
LUANDA: AD Ports Group, today began its long-term management and development of a major multipurpose terminal and an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback